Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib

R Bartsch; N Harbeck; D Wrobel; M Zaiss; J Terhaag; D Guth; A Distelrath; R Wuerstlein; MO Zahn; D Luftner; M Schwitter; M Balic; C Jackisch; V Muller; Gabriel Rinnerthaler; M Schmidt; K Zaman; T Schinkothe; M Gorray; U Breitenstein

Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib

R Bartsch, N Harbeck, D Wrobel, M Zaiss, J Terhaag, D Guth, A Distelrath, R Wuerstlein, MO Zahn, D Luftner, M Schwitter, M Balic, C Jackisch, V Muller, Gabriel Rinnerthaler, M Schmidt, K Zaman, T Schinkothe, M Gorray, U Breitenstein

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	S20-S21
Journal	BREAST
Volume	68
Publication status	Published - 2023

Cite this

Bartsch, R., Harbeck, N., Wrobel, D., Zaiss, M., Terhaag, J., Guth, D., Distelrath, A., Wuerstlein, R., Zahn, MO., Luftner, D., Schwitter, M., Balic, M., Jackisch, C., Muller, V., Rinnerthaler, G., Schmidt, M., Zaman, K., Schinkothe, T., Gorray, M., & Breitenstein, U. (2023). Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib. BREAST , 68, S20-S21.

Bartsch, R ; Harbeck, N ; Wrobel, D et al. / Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib. In: BREAST 2023 ; Vol. 68. pp. S20-S21.

@article{580ce43960514ce2aece2ea4f0cd79c6,

title = "Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib",

author = "R Bartsch and N Harbeck and D Wrobel and M Zaiss and J Terhaag and D Guth and A Distelrath and R Wuerstlein and MO Zahn and D Luftner and M Schwitter and M Balic and C Jackisch and V Muller and Gabriel Rinnerthaler and M Schmidt and K Zaman and T Schinkothe and M Gorray and U Breitenstein",

year = "2023",

language = "English",

volume = "68",

pages = "S20--S21",

journal = "BREAST ",

issn = "0960-9776",

}

Bartsch, R, Harbeck, N, Wrobel, D, Zaiss, M, Terhaag, J, Guth, D, Distelrath, A, Wuerstlein, R, Zahn, MO, Luftner, D, Schwitter, M, Balic, M, Jackisch, C, Muller, V, Rinnerthaler, G, Schmidt, M, Zaman, K, Schinkothe, T, Gorray, M & Breitenstein, U 2023, 'Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib', BREAST , vol. 68, pp. S20-S21.

Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib. / Bartsch, R; Harbeck, N; Wrobel, D et al.
In: BREAST , Vol. 68, 2023, p. S20-S21.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib

AU - Bartsch, R

AU - Harbeck, N

AU - Wrobel, D

AU - Zaiss, M

AU - Terhaag, J

AU - Guth, D

AU - Distelrath, A

AU - Wuerstlein, R

AU - Zahn, MO

AU - Luftner, D

AU - Schwitter, M

AU - Balic, M

AU - Jackisch, C

AU - Muller, V

AU - Rinnerthaler, Gabriel

AU - Schmidt, M

AU - Zaman, K

AU - Schinkothe, T

AU - Gorray, M

AU - Breitenstein, U

PY - 2023

Y1 - 2023

M3 - Abstract (Journal)

SN - 0960-9776

VL - 68

SP - S20-S21

JO - BREAST

JF - BREAST

ER -

Bartsch R, Harbeck N, Wrobel D, Zaiss M, Terhaag J, Guth D et al. Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib. BREAST . 2023;68:S20-S21.